![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, August 23, 2013 3:08:05 PM
As the population ages, the market for Alzheimer's and cognitive disorders is exploding.
Current treatments stabilize symptoms only for a short period of time.
What is on the horizon for symptom improvement and disease modification from drug and device companies?
Session Chair: Christian Hordo, Senior Manager Business Development, Genentech
Genentech's mission is to develop drugs to address significant unmet medical
needs
Bjorn Larsson, Executive Chairman, Alzinova
Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease
Hendrik Leibers, CFO, Probiodrug
Probiodrug AG is a biopharmaceutical company focused on the development of innovative oral drugs for the treatment of major age related diseases.
Koen de Witte, Managing Director, reMYND
reMYND drives the development of disease-modifying treatments against Alzheimer's, Parkinson's, Diabetes and other protein misfolding disorders
Gerald Commissiong, President & CEO, Amarantus Bioscience
Out of the 4 companies above, Amarantus is the best fit for a device company since it owns the Lympro Test, which is a device; a diagnostic product. Gerald could present the latest data from DBX and talk about the LymPro Test Kit. Doesn't sound right to talk about the old data
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM